# US 2026/0098302 A1 · Methods for targeted sequencing of cell-free dna

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098302 A1
- Document ID: US20260098302A1
- Status: Published application
- Kind: A1
- Application number: 19/399,492
- Filed: 2025-11-24
- Published: 2026-04-09
- Earliest claimed: 2005-07-29
- Assignees: Natera, Inc.
- Applicants: Natera, Inc.
- Inventors: Matthew RABINOWITZ; Matthew Micah HILL; Bernhard ZIMMERMANN; Johan BANER; George GEMELOS; Milena BANJEVIC; Allison RYAN; Styrmir SIGURJONSSON; Zachary DEMKO
- Web page: https://patentgrep.com/patent/US20260098302A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- G16B 20/10: Ploidy or copy number detection
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6855: Ligating adaptors
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6869: Methods for sequencing
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 25/00: ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B 40/20: Supervised data analysis
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The invention provides methods for simultaneously enriching multiple target regions of interest in one reaction volume, from cell-free DNA isolated from a blood or plasma sample, followed by high-thought sequencing and sequence read analysis. The invention also provides library of target-specific oligonucletotide primers or probes for the multiplexed target enrichment.

## Claims

### Claim 1

A method for targeted sequencing of cell-free DNA, comprising:
appending at least one adaptor to cell-free DNA extracted from a blood or plasma sample of a human subject to generate adapted DNA;
performing targeted enrichment on the adapted DNA, wherein the targeted enrichment comprises (i) contacting adapted DNA with a library comprising oligonucleotides that specifically hybridize to at least 800 different target loci, wherein a target locus comprises a variant position, and (ii) amplifying adapted DNA that was contacted in step (i) in the same reaction volume to generate enriched DNA; and
determining the sequence of at least some of the enriched DNA or DNA derived therefrom by performing high-throughput sequencing to generate sequence reads.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method further comprises analyzing the sequence reads and identifying one or more variants from the sequence reads.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cell-free DNA comprises cell-free DNA derived from both normal and cancer cells of the human subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the library comprises oligonucleotides that specifically hybridize to at least 1,200 different target loci comprising single nucleotide variant positions on one or more chromosomes.

### Claim 5 (depends on 1)

The method of claim 1, wherein the library comprises oligonucleotides that specifically hybridize to 1,000 to 20,000 different target loci comprising single nucleotide variant positions on one or more chromosomes.

### Claim 6 (depends on 1)

The method of claim 1, wherein the library comprises oligonucleotides that specifically hybridize to 1,000 to 10,000 different target loci comprising single nucleotide variant positions on one or more chromosomes.

### Claim 7 (depends on 1)

The method of claim 1, wherein the concentration of each target locus-specific oligonucleotide in the library is 5 nM or less.

### Claim 8 (depends on 1)

The method of claim 1, wherein the high-throughput sequencing is sequencing-by-synthesis.

### Claim 9 (depends on 1)

The method of claim 1, wherein at least 90% of the sequence reads comprise the variants at loci specifically hybridized by the oligonucleotides.

### Claim 10 (depends on 1)

The method of claim 1, wherein at least 95% of the sequence reads comprise the variants at loci specifically hybridized by the oligonucleotides.

### Claim 11 (depends on 1)

The method of claim 1, wherein the at least one adaptor comprises a universal priming sequence.

### Claim 12 (depends on 11)

The method of claim 11, wherein the method further comprises amplifying adapted DNA using the universal priming sequence prior to performing targeted enrichment.

### Claim 13

A method for targeted sequencing of cell-free DNA, comprising:
tagging cell-free DNA extracted from a biological sample from a human subject with molecular barcodes to generate tagged DNA;
performing targeted enrichment on the tagged DNA, wherein the targeted enrichment comprises (i) contacting tagged DNA with a library comprising oligonucleotides that specifically hybridize to at least 800 different target loci, wherein a target locus comprises a variant position, and (ii) amplifying tagged DNA that was contacted in step (i) in the same reaction volume to generate enriched DNA;
determining the sequence of at least some of the enriched DNA or DNA derived therefrom by performing high-throughput sequencing to generate sequence reads.

### Claim 14 (depends on 13)

The method of claim 13, wherein the method further comprises analyzing the sequence reads and identifying one or more variants from the sequence reads.

### Claim 15 (depends on 13)

The method of claim 13, wherein the cell-free DNA comprises cell-free DNA derived from both normal and cancer cells of the human subject.

### Claim 16 (depends on 13)

The method of claim 13, wherein the library comprises oligonucleotides that specifically hybridize to at least 1,200 different target loci comprising single-nucleotide-variant positions on one or more chromosomes.

### Claim 17 (depends on 13)

The method of claim 13, wherein the library comprises oligonucleotides that specifically hybridize to 1,000 to 20,000 different target loci comprising single-nucleotide-variant positions on one or more chromosomes.

### Claim 18 (depends on 13)

The method of claim 13, wherein the library comprises oligonucleotides that specifically hybridize to 1,000 to 10,000 different target loci comprising single-nucleotide-variant positions on one or more chromosomes.

### Claim 19 (depends on 13)

The method of claim 13, wherein the concentration of each target-specific oligonucleotide in the library of target-specific oligonucleotides is 5 nM or less.

### Claim 20 (depends on 13)

The method of claim 13, wherein the high-throughput sequencing is sequencing-by-synthesis.

### Claim 21 (depends on 13)

The method of claim 13, wherein at least 90% of the sequence reads comprises the variants at loci specifically hybridized by the oligonucleotides.

### Claim 22 (depends on 13)

The method of claim 13, wherein at least 95% of the sequence reads comprises the variants at loci specifically hybridized by the oligonucleotides.

### Claim 23 (depends on 13)

The method of claim 13, wherein the tagged DNA are tagged with up to 1024 different molecular barcodes.

### Claim 24 (depends on 13)

The method of claim 13, wherein the tagged DNA are tagged with 1024 to 65536 different molecular barcodes.
